Efficacy of EXPAREL vs. Bupivacaine

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

August 31, 2029

Study Completion Date

August 31, 2029

Conditions
Total Ankle ArthroplastyPostsurgical Analgesia
Interventions
DRUG

EXPAREL

EXPAREL (bupivacaine liposome injectable suspension) is formulated as a sterile, non-pyrogenic, white to off-white, preservative-free homogenous suspension of bupivacaine encapsulated into multivesicular liposomes (pMVL drug delivery system). For this study, EXPAREL will be provided in 20 mL (266 mg) EXPAREL single-use, clear glass vials.

DRUG

0.25% bupivacaine (HCl): 50 ml

The reference product is 50 mL (125 mg) 0.25% bupivacaine HCl administered via a combined sciatic (in the popliteal fossa) and saphenous nerve block (in the adductor canal)

DRUG

0.25% bupivacaine (HCl): 30 ml

EXPAREL admixed with 30 mL (75 mg) 0.25% bupivacaine HCl

Trial Locations (1)

30329

Emory University Orthopaedic Hospital Musculoskeletal Institute (MSK), Atlanta

Sponsors
All Listed Sponsors
collaborator

Pacira Pharmaceuticals, Inc

INDUSTRY

lead

Emory University

OTHER

NCT07212114 - Efficacy of EXPAREL vs. Bupivacaine | Biotech Hunter | Biotech Hunter